Mischel Lab

The Mischel lab studies extrachromosomal oncogene amplification and altered metabolism in cancer.
Account managed by lab members. Retweets are not endorsement.

[Mischel Lab @mischellab]

The Paul Mischel Laboratory has relocated to ChEM-H at Stanford @Stanford_ChEMH.
Paul is Professor and Vice Chair of Research for the Department of Pathology, Stanford University School of Medicine @StanfordMed and Institute Scholar, ChEM-H, Stanford University.

[Cancer Grand Challenges @CancerGrand]

The eDyNAmiC team will investigate #ecDNA, found in around a third of cancers, hoping to develop much needed treatments for people whose cancer is driven in this way

Congratulations Paul Mischel (@mischellab @StanfordMed) and the team, funded by @CR_UK and @theNCI

3/n

[WeiniHuang @huang_weini]

It is very exciting to be part of the eDyNAmiC team to take the #CancerGrandChallenges and trackle cancer evolution driven by ecDNA. Thanks for the big support of @CancerGrand @QMULMaths @QMBCI

[Roel Verhaak @roelverhaak]

Looking forward to working with @anton_gh, @michelle_monje, @huang_weini, @MariamJHanjani, @SihanSean, @BenjaminWerner_, @HowardYChang, @cbailey_58, @VineetBafna3, and many others.

[Mischel Lab @mischellab]

We are honored, grateful for the opportunity, and committed to working together to make a difference for patients with ecDNA-driven cancers. It is a thrill to work with such an amazing group of colleagues.

[Mischel Lab @mischellab]

We are excited to share that the eDyNAmiC team has been chosen as a @CancerGrand, @theNCI & @CR_UK winner! #CancerGrandChallenges

[Cancer Research UK @CR_UK]

Extrachromosomal DNA (ecDNA) are small rings of DNA that help tumours evolve and evade treatment.

The eDyNAmiC team will look at ways to interfere with ecDNA, slow down tumour development & ultimately bring hope to patients whose cancers have become resistant to treatment.

4/6

[Mischel Lab @mischellab]

@CancerGrand @theNCI @CR_UK The team, composed of investigators from 11 institutions across the US, UK, and Germany, will leverage our interdisciplinary expertise to tackle the questions of origin, function, and evolution of ecDNA in cancer.

[Mischel Lab @mischellab]

Congratulations to @kinglhung, @KatieEYost, @HowardYChang and colleagues on this landmark discovery published today in @Nature. We are thrilled to have worked together with you on this.

[King L Hung @kinglhung]

Our paper is out in @Nature! Extrachromosomal DNA molecules huddle together in cancer cells to activate oncogene expression (which we call ecDNA hubs). A great collaboration with @KatieEYost, @HowardYChang, @549nm, Zhe Liu, and others. (1/10) https://t.co/FGMYDEfUmx

[Sihan Wu 吴思涵 @SihanSean]

Congrats to my former colleague Junfeng Bi @mischellab for the new paper! He found that GBM, the most lethal brain tumor, is sensitive to SMPD1 inhibition. Adding antidepressant fluoxetine to standard-of-care chemotherapy can improve patient survival.
https://t.co/9WWTrWSq9o

[Mischel Lab @mischellab]

The idea that a safe, inexpensive, and highly brain penetrant drug could make a difference for glioblastoma patients is exciting, compelling, and needs to be further studied! #Glioblastoma #CancerResearch #Cancer

[Mischel Lab @mischellab]

Congratulations to postdoc Junfeng Bi on his new paper out today in @CellReports! It has important mechanistic and clinical implications for glioblastoma patients, spanning from fundamental biology, to clinical data.
@Stanford_ChEMH @StanfordPath

https://t.co/N8tA8l20HY

[Mischel Lab @mischellab]

The team found that GBMs are sensitive to SMPD1 inhibition and that fluoxetine can safely and potently shrink GBM tumors in mice. We also used real world data to identify that addition of fluoxetine to standard of care improves patient survival.

[Mischel Lab @mischellab]

We are thrilled to join the wonderful @Stanford_ChEMH community to continue our research into extrachromosomal DNA!

[Sarafan ChEM-H @Stanford_ChEMH]

We are delighted to welcome extrachromosomal DNA pioneer Paul Mischel @mischellab to ChEM-H! Mischel spoke to us about looking where the light isn’t being shone and how genetic SpaghettiOs give cancers an advantage: https://t.co/FChBpDpTYu
@StanfordPath @StanfordMed

[Jens Luebeck @Jens_Luebeck]

Excited to see this paper out. Joint work led by the @CalifanoMd and @VineetBafna3 labs. We characterized frequent human-HPV hybrid circular extrachromosomal DNA #ecDNA in HPV+ oropharyngeal cancer patients.
https://t.co/LhwU42cmJv

[NatureRevClinOncol @NatRevClinOncol]

In uveal melanoma, PRC1 loss leads to gene de-repression, chromosome segregation errors, CIN, rupture-prone micronuclei & release of dsDNA into the cytosol, which activates the cGAS-STING pathway to induce inflammatory signalling & confers a poor prognosis https://t.co/1XuUP2nPbR

[Ashley Laughney @LaughneyLab]

(1/2) Insights from #scRNAseq, coupled with fundamental #cell_biology, reveals loss of #PRC1 in a subset of tumor cells underlies transition of #uveal #melanoma from indolent to #metastatic phenotype. https://t.co/HTnDqx4xk2 A team effort with @Samuel_Bakhoum @mischellab

[Mischel Lab @mischellab]

This collaborative work was led by @MathieuBakhoum, an alumni of our lab and now a physician scientist @Yale with @LaughneyLab @WeillCornell and @Samuel_Bakhoum @sloan_kettering

#Cancer #Melanoma

[Mischel Lab @mischellab]

Congratulations to @MathieuBakhoum on the new paper, which has significant clinical implications for uveal #Melanoma patients, published in @NatureComms.
This work functionally links two hallmarks of cancer #epigenetic dysregulation and chromosomal instability.
#cancerresearch

[Mathieu Bakhoum @MathieuBakhoum]

Uveal #Melanoma can metastasize.
But why do these highly lethal metastases occur in some patients but not others?
In our new paper @NatureComms we describe a novel and unanticipated mechanism.
#epigenetics
@YaleMed @LaughneyLab @Samuel_Bakhoum @mischellab
https://t.co/RxKIIZeQmP

[Mischel Lab @mischellab]

We are thrilled to announce that @MathieuBakhoum joined @YaleMed as Assistant Professor.
Congratulations Mathieu and best wishes on your next and exciting endeavor @Yale!
His lab is recruiting! Apply if you are interested in #melanoma and #epigenetics

https://t.co/2ieehYiMNP

[Mathieu Bakhoum @MathieuBakhoum]

Delighted to announce that I joined @YaleMed as Assistant Professor in @YaleOph.
My laboratory will focus on two research areas with direct clinical applications.

#AcademicTwitter #ophthotwitter #Ophthalmology #retina
https://t.co/E5SKc4pieP

1/4

[Mathieu Bakhoum @MathieuBakhoum]

Thankful for the outstanding mentorship I received from Paul Mischel @mischellab and colleagues @UCSDHealth.

And looking forward to making new friendships and collaborations @Yale.

New Haven, here we come!

4/4

[Mischel Lab @mischellab]

Very honored that our grant proposal on #ecDNA in cancer is shortlisted for the #CancerGrandChallenges prize!
Grateful to the @CancerGrand.
Thank you to all of our team members! And Looking forward to the exciting work ahead.

[Cancer Grand Challenges @CancerGrand]

BREAKING NEWS: today we announce 11 teams selected to compete for our awards! Winners receive up to £20m each and the freedom to unleash their scientific creativity, conducting research that transcends geography and discipline - https://t.co/N1jzeKXz0o #CancerGrandChallenges